atuveciclib and ly share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.158 means 16% of the combined target set is bound by both compounds. The IDF-weighted score of 0.136 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do atuveciclib and ly have in common?
atuveciclib and ly share 3 molecular targets with a Jaccard similarity of 16%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can atuveciclib and ly be combined?
atuveciclib and ly share 3 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: atuveciclib or ly?
Both atuveciclib and ly have substantial PubMed research. View their individual profiles for full evidence scores.